{"pmid":32381478,"pmcid":"PMC7167542","title":"Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic.","text":["Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic.","Vaccine","Hosangadi, Divya","Warmbrod, Kelsey Lane","Martin, Elena K","Adalja, Amesh","Cicero, Anita","Inglesby, Thomas","Watson, Crystal","Watson, Matthew","Connell, Nancy","32381478"],"journal":"Vaccine","authors":["Hosangadi, Divya","Warmbrod, Kelsey Lane","Martin, Elena K","Adalja, Amesh","Cicero, Anita","Inglesby, Thomas","Watson, Crystal","Watson, Matthew","Connell, Nancy"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32381478","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.vaccine.2020.04.037","keywords":["covid-19","mass vaccination","pandemic","vaccines"],"topics":["Treatment"],"weight":1,"_version_":1666419683397468160,"score":9.490897,"similar":[{"pmid":32186952,"pmcid":"PMC7103671","title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.","text":["COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.","The novel coronavirus infection (COVID-19 or Coronavirus disease 2019) that emerged from Wuhan, Hubei province of China has spread to many countries worldwide. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS in the past decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt this emerging virus infection.","Hum Vaccin Immunother","Dhama, Kuldeep","Sharun, Khan","Tiwari, Ruchi","Dadar, Maryam","Malik, Yashpal Singh","Singh, Karam Pal","Chaicumpa, Wanpen","32186952"],"abstract":["The novel coronavirus infection (COVID-19 or Coronavirus disease 2019) that emerged from Wuhan, Hubei province of China has spread to many countries worldwide. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS in the past decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt this emerging virus infection."],"journal":"Hum Vaccin Immunother","authors":["Dhama, Kuldeep","Sharun, Khan","Tiwari, Ruchi","Dadar, Maryam","Malik, Yashpal Singh","Singh, Karam Pal","Chaicumpa, Wanpen"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32186952","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1080/21645515.2020.1735227","keywords":["covid-19","emerging coronavirus","drugs","therapeutics","vaccines"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138492524036096,"score":51.389038},{"pmid":32485211,"title":"Advances in skin science enable the development of a COVID-19 Vaccine.","text":["Advances in skin science enable the development of a COVID-19 Vaccine.","J Am Acad Dermatol","Falo, Louis D Jr","32485211"],"journal":"J Am Acad Dermatol","authors":["Falo, Louis D Jr"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32485211","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jaad.2020.05.126","topics":["Treatment"],"weight":1,"_version_":1668532114757255168,"score":48.1603},{"pmid":32344056,"pmcid":"PMC7194727","title":"Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination.","text":["Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination.","Eosinophils are circulating and tissue-resident leukocytes that have potent pro-inflammatory effects in a number of diseases. Recently, eosinophils have been shown to have a variety of other functions, including immunoregulation and antiviral activity. Eosinophil levels vary dramatically in a number of clinical settings, especially following eosinophil-targeted therapy, which is now available to selectively deplete these cells. There are key COVID-19-related questions concerning eosinophils whose answers affect recommended prevention and care. First, do patients with eosinophilia-associated diseases have an altered course of COVID-19? Second, do patients with eosinopenia (now intentionally induced by biological drugs) have unique COVID-19 susceptibility and/or disease course? This is a particularly relevant question as eosinopenia is associated with acute respiratory deterioration during infection with the Severe Acute Respiratory Syndrome (SARS)-Corona Virus (CoV)-2, the causative agent of COVID-19. Third, do eosinophils contribute to the lung pathology induced during COVID-19 and will they contribute to immunopotentiation potentially associated with emerging COVID-19 vaccines? Herein, we address these timely questions and project considerations during the emerging COVID-19 pandemic.","J Allergy Clin Immunol","Lindsley, Andrew W","Schwartz, Justin T","Rothenberg, Marc E","32344056"],"abstract":["Eosinophils are circulating and tissue-resident leukocytes that have potent pro-inflammatory effects in a number of diseases. Recently, eosinophils have been shown to have a variety of other functions, including immunoregulation and antiviral activity. Eosinophil levels vary dramatically in a number of clinical settings, especially following eosinophil-targeted therapy, which is now available to selectively deplete these cells. There are key COVID-19-related questions concerning eosinophils whose answers affect recommended prevention and care. First, do patients with eosinophilia-associated diseases have an altered course of COVID-19? Second, do patients with eosinopenia (now intentionally induced by biological drugs) have unique COVID-19 susceptibility and/or disease course? This is a particularly relevant question as eosinopenia is associated with acute respiratory deterioration during infection with the Severe Acute Respiratory Syndrome (SARS)-Corona Virus (CoV)-2, the causative agent of COVID-19. Third, do eosinophils contribute to the lung pathology induced during COVID-19 and will they contribute to immunopotentiation potentially associated with emerging COVID-19 vaccines? Herein, we address these timely questions and project considerations during the emerging COVID-19 pandemic."],"journal":"J Allergy Clin Immunol","authors":["Lindsley, Andrew W","Schwartz, Justin T","Rothenberg, Marc E"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344056","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jaci.2020.04.021","keywords":["covid-19","coronavirus","eosinophils","hyperimmune","immunopathology","immunopotentiation","sars","vaccines"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495829147651,"score":47.89031},{"pmid":32387332,"title":"Current development of COVID-19 diagnostics, vaccines and therapeutics.","text":["Current development of COVID-19 diagnostics, vaccines and therapeutics.","A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei Province, China, in late December 2019. The rapidly increasing number of cases has caused worldwide panic. In this review, we describe some currently applied diagnostic approaches, as well as therapeutics and vaccines, to prevent, treat and control further outbreaks of SARS-CoV-2 infection.","Microbes Infect","Zhang, Naru","Li, Chaoqun","Hu, Yue","Li, Kangchen","Liang, Jintian","Wang, Lili","Du, Lanying","Jiang, Shibo","32387332"],"abstract":["A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei Province, China, in late December 2019. The rapidly increasing number of cases has caused worldwide panic. In this review, we describe some currently applied diagnostic approaches, as well as therapeutics and vaccines, to prevent, treat and control further outbreaks of SARS-CoV-2 infection."],"journal":"Microbes Infect","authors":["Zhang, Naru","Li, Chaoqun","Hu, Yue","Li, Kangchen","Liang, Jintian","Wang, Lili","Du, Lanying","Jiang, Shibo"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387332","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.micinf.2020.05.001","keywords":["sars-cov-2","diagnostic approaches","therapeutics","vaccines"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666428892251947008,"score":47.278828},{"pmid":32480250,"title":"Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.","text":["Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.","Med Hypotheses","Meenakshisundaram, Ramachandran","Senthilkumaran, Subramanian","Thirumalaikolundusubramanian, Ponniah","32480250"],"journal":"Med Hypotheses","authors":["Meenakshisundaram, Ramachandran","Senthilkumaran, Subramanian","Thirumalaikolundusubramanian, Ponniah"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32480250","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109849","keywords":["bcg","coronavirus","covid-19","measles","sars","vaccines"],"topics":["Treatment"],"weight":1,"_version_":1668437834947624960,"score":47.187668}]}